8-K 1 v327908_8-k.htm FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

 

FORM 8-K

_____________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 8, 2012

 

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other Jurisdiction

of Incorporation)

001-32639

(Commission File Number)

 

36-3898269

(IRS Employer Identification No.)

 

787 Seventh Ave, 48th Floor

New York, New York 10019

(Address of Principal Executive Offices)

 

(212) 554-4484

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£Written communications pursuant to Rule 425 under the Securities Act.
£Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

   
 
Item 2.02.Results of Operations and Financial Condition.

 

On November 8, 2012, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the third quarter ended September 30, 2012. TG also announced that on Friday, November 9, 2012 at 8:30am EST, TG will host an investor conference call during which the Company will provide a brief financial overview of its third quarter financial results and a business outlook for the remainder of 2012. A copy of such press release is being furnished as Exhibit 99.1.

 

Item 9.01Financial Statements And Exhibits.

 

(d)Exhibits.

 

99.1Press release issued by TG Therapeutics, Inc., dated November 8, 2012.
- 2 -
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  TG Therapeutics, Inc.  
  (Registrant)  
       
       
       
Date: November 8, 2012      
       
  By: /s/ Sean A. Power  
    Sean A. Power  
    Chief Financial Officer  

 

 

 

 

- 3 -
 

INDEX TO EXHIBITS

 

 

Exhibit

NumberDescription

 

99.1Press release issued by TG Therapeutics, Inc., dated November 8, 2012.

 

 

- 4 -